Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5771828 | 0.92 | GSK3B (0.42) | GSK3BSMN1; SMN2NAMPTMAPTALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5775717 | 0.91 | GSK3B (0.44) | GSK3BSMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL5774473 | 0.91 | CYP3A4 (0.52) | GSK3BSMN1; SMN2NAMPTSORT1MAPT | |
| SCHEMBL5775471 | 0.87 | HDAC3 (0.46) | GSK3BSMN1; SMN2HDAC6HDAC1HDAC3 | |
| Trifluoroacetic Acid SCHEMBL5771101 | 0.86 | TP53 (0.46) | GSK3BSMN1; SMN2NAMPTHDAC6MAPT | |
| Trifluoroacetic Acid SCHEMBL5774568 | 0.85 | LMNA (0.50) | SMN1; SMN2SORT1MAPTALDH1A1GAA | |
| Trifluoroacetic Acid SCHEMBL5773866 | 0.84 | ALDH1A1 (0.48) | SMN1; SMN2SORT1MAPTALDH1A1GAA | |
| Trifluoroacetic Acid SCHEMBL5773568 | 0.83 | EPHX2 (0.52) | NAMPTGAACYP1A2CYP2C9CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL5773317 | 0.82 | CYP3A4 (0.53) | SMN1; SMN2MAPTALDH1A1GAACYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5775554 | 0.82 | HDAC4 (0.43) | SMN1; SMN2HDAC6HDAC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | GSK3B 1517/4885SMN1; SMN2 3383/4885NAMPT 2451/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | GSK3B 2013/4885SMN1; SMN2 2449/4885NAMPT 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.